BioSpace News Archive

Protalix BioTherapeutics, Inc. announced that the Company’s management and Board of Directors have decided that it is in the best interest of the Company to voluntarily delist its common stock from the Tel Aviv Stock Exchange.

Integra LifeSciences Holdings Corporation, a leading global medical technology company, announced that Jan De Witte, president and chief executive officer will present at the 41st Annual J.P. Morgan Healthcare conference on January 11, 2023 at 7:30pm ET.

Quipt Home Medical Corp., a U.S. based home medical equipment provider, focused on end-to-end respiratory care, announced its fourth quarter and fiscal year 2022 financial results and operational highlights.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), announced today that the FDA has granted BTD to adagrasib in combination with cetuximab in patients with KRASG12C-mutated, advanced CRC whose cancer has progressed following prior treatment with chemotherapy and an anti-VEGF therapy.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, announced its support for a recent guideline update by the International Society for Heart and Lung Transplantation (ISHLT), which includes the use of donor-derived cfDNA (dd-cfDNA) testing for surveillance of heart transplant recipients.

Osmol Therapeutics, today announced that it is presenting at BIOTECH SHOWCASE 2023, a leading investor conference focused on driving advances in therapeutic development taking place in San Francisco from January 9-11, 2023.

Paige today announced it has published the results of a pivotal study demonstrating accuracy gains in pathologists’ diagnosis of prostate cancer when using Paige Prostate Detect, an FDA-authorized AI software that assists pathologists in the detection of foci that are suspicious for cancer during the review of scanned whole slide images (WSI) from prostate needle biopsies.

The global life science analytics market size was exhibited at USD 9.34 billion in 2022 and it is expected to hold around USD 18.12 billion by 2030, growing at a CAGR of 8.68% from 2022 to 2030.

Curium, the world’s leading nuclear medicine company, announced that with the successful restarting of the BR2 research reactor in Belgium on 20 December, Curium’s supply of molybdenum-99 and iodine-131 is continuing as usual.

The brain cancer, glioblastoma, is a fierce and formidable opponent. Its millions of victims include Senator John McCain, President Biden’s son, Beau, and famed film critic Gene Siskel, to name just a few.